Hepatitis C: all 2,356 studies
Page 14 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- Swiss HCVree TrialCompletedNCT02785666Phase 3
- Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical PracticeCompletedNCT02783976
- Dynamic Liver Tests in Liver DiseaseCompletedNCT02782247
- Study to Describe the Actual Situation of Hepatitis C Treatment in BrazilCompletedNCT02773394
- Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4Status unknownNCT02772744
- A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral SuppressionCompletedNCT02772328Not applicable
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionActive, not recruitingNCT02772003Phase 1
- Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)CompletedNCT02768961Phase 4
- Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)Status unknownNCT02768545Phase 4
- Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin LymphomasWithdrawnNCT02762448
- A Study of CDI-31244: A Novel NNI in HV and HCV Infected SubjectsCompletedNCT02760758Phase 1
- Extrahepatic Insulin Resistance in Chronic Hepatitis CCompletedNCT02760355Not applicable
- Impact of Antiviral Therapy on Gastroesophageal Varices.CompletedNCT02758509
- Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject DrugsCompletedNCT02755402Not applicable
- Counseling and Reminders for Regular HIV and STIs ScreeningCompletedNCT02752152Not applicable
- Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)CompletedNCT02749864
- Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)Status unknownNCT02745132Phase 4
- Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis CCompletedNCT02744560Not applicable
- Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis CCompletedNCT02744547Not applicable
- Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis CCompletedNCT02744105Not applicable
- Evaluation of HepCure Toolkit to Improve Harvoni AdherenceCompletedNCT02740556Not applicable
- Pilot HCV Direct Acting Antiviral Therapy and MetabolismCompletedNCT02734173Phase 4
- Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated CirrhosisStatus unknownNCT02732405Phase 3
- Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in KoreaCompletedNCT02727933
- Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in BloodCompletedNCT02718573
- A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionCompletedNCT02716428Phase 2
- SR-BI and Antiviral Treatment Response in HCVCompletedNCT02714712
- Testing and Treating Hepatitis C in Community PharmaciesCompletedNCT02706223Not applicable
- Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1CompletedNCT02705534Phase 3
- Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune DiseaseStatus unknownNCT02691728Phase 4
- Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCVCompletedNCT02690103Phase 2
- Chronic Hepatitis B and C Recall Northern HollandStatus unknownNCT02687061
- Study of Hepatitis C Treatment During PregnancyCompletedNCT02683005Phase 1
- Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCRCompletedNCT02669966Not applicable
- HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-InfectionCompletedNCT02660905Phase 3
- Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver DiseaseWithdrawnNCT02658786
- Reviewing DAA Efficacy Managing Patient Treatment In Online NeighbourhoodsStatus unknownNCT02657694
- EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C PatientsCompletedNCT02652377Phase 1
- Impact of Hepatitis C Virus Therapy on Central Nervous System OutcomesCompletedNCT02650024
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") FailuresStatus unknownNCT02646111Phase 3
- Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.CompletedNCT02641158Not applicable
- Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis CStatus unknownNCT02639585Phase 4
- Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution TherapyStatus unknownNCT02638233Phase 4
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedNCT02634008Phase 3
- Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1CompletedNCT02629172
- Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)CompletedNCT02628717
- Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, CambodiaTerminatedNCT02628691
- Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)CompletedNCT02624063Phase 4
- Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject DrugsCompletedNCT02609893Phase 4
- An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV InfectionCompletedNCT02597270
- Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 InfectionCompletedNCT02597166Phase 3
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedNCT02596880Phase 3
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedNCT02593162Phase 2
- Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaCompletedNCT02592057
- Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT02591277
- Viral Load Changes in Lymphoma Patients With HCV Infection After ChemotherapyStatus unknownNCT02588560
- Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of TenofovirCompletedNCT02588287Not applicable
- Switching Regimen in Treating Cirrhotic HCV GT1b SubjectsCompletedNCT02583685Phase 2
- Project BEST: Buprenorphine Entry Into Substance Abuse TreatmentCompletedNCT02583243
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese SubjectsCompletedNCT02581020
- The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal FailureCompletedNCT02580474Phase 4
- Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)CompletedNCT02578693
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected PatientsCompletedNCT02576314Phase 3
- Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope GlycoproteinsCompletedNCT02574884Not applicable
- Antiviral Pharmacology and Adherence in Drug UsersCompletedNCT02573376Not applicable
- C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey StudyTerminatedNCT02568540
- A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive IndividualsCompletedNCT02568332Phase 1
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatCompletedNCT02565888Phase 1
- A Drug-drug Interaction Study Between Daclatasvir and MetforminCompletedNCT02565862Phase 1
- Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement TherapyWithdrawnNCT02563665
- Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02562742
- A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedNCT02555943Phase 2/3
- The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary HospitalCompletedNCT02555475Not applicable
- A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WithdrawnNCT02551861Phase 2
- Quantification of Side Effects During Hepatitis C TherapyCompletedNCT02545400
- Hepatitis C Virus in Neutrophil Granulocyte Progenitor CellsWithdrawnNCT02545387
- Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis CCompletedNCT02545335
- Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02537379
- Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV DrugsCompletedNCT02532907
- Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization PeriodCompletedNCT02531269
- Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis CCompletedNCT02528461
- Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis CCompletedNCT02526641
- A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy VolunteersCompletedNCT02512562Phase 1
- Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in AndalusiaStatus unknownNCT02511496
- A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsTerminatedNCT02510300
- First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis CTerminatedNCT02510248Phase 1
- Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus RibavirinCompletedNCT02508090
- Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular CarcinomaStatus unknownNCT02507882Not applicable
- Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA RegimensCompletedNCT02505243
- A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02498015Phase 4
- A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
- Outcome of New Direct Acting Agents For Hepatitis C A Community Based ExperienceStatus unknownNCT02485262
- Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1WithdrawnNCT02485080Phase 4
- Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedNCT02483156Phase 2/3
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected PatientsCompletedNCT02482077Phase 4
- Neutrino Regimen for Treatment-experienced HCV GT1 PatientsCompletedNCT02480686Phase 4
- Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)TerminatedNCT02478229Phase 3
- A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in WisconsinCompletedNCT02474043Not applicable